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Available online 14 March 2016Background: Chronic muscle pain affects close to 20% of the population and is a major health burden. The
underlying mechanisms of muscle pain are difficult to investigate as pain presents in patients with very diverse
histories. Treatment options are therefore limited andnot tailored to underlyingmechanisms. Togain insight into
the pathophysiology of myalgia we investigated a homogeneous group of patients suffering from myotonic
dystrophy type 2 (DM2), a monogenic disorder presenting with myalgia in at least 50% of affected patients.
Methods: After IRB approval we performed an observational cross-sectional cohort study and recruited 42
patients with genetically confirmed DM2 plus 20 healthy age and gender matched control subjects. All partici-
pants were subjected to an extensive sensory-testing protocol. In addition, RNA sequencing was performed
from 12 muscle biopsy specimens obtained from DM2 patients.
Findings: Clinical sensory testing as well as RNA sequencing clearly separated DM2 myalgic from non-myalgia
patients and also from healthy controls. In particular pressure pain thresholds were significantly lowered for
all muscles tested in myalgic DM2 patients but were not significantly different between non-myalgic patients
and healthy controls. The expression of fourteen muscle expressed genes in myalgic patients was significantly
up or down-regulated in myalgic compared to non-myalgic DM2 patients.
Interpretation: Our data support the idea that molecular changes in the muscles of DM2 patients are associated
withmuscle pain. Further studies should addresswhethermuscle-specific molecular pathways play a significant
role in myalgia in order to facilitate the development of mechanism-based therapeutic strategies to treat
musculoskeletal pain.
Funding: This study was funded by the German Research Society (DFG, GK1631), KAP programme of Charité
Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chronic pain affects 11–24% of the world's population and as such
represents a major burden on health services (Breivik et al., 2006). A
substantial proportion of pain patients suffer from musculoskeletal
pain (McBeth and Jones, 2007). Treatments formuscle pain andmyalgia
are often ineffective and have not been tailored to treat painwhich is as-
sociatedwith a diverse range of pathologies. In order to gain insight into
themolecular pathology of pain in a genetically uniform groupwe have
studied patients with myotonic dystrophy type 2 (DM2) (Udd andnit, Experimental and Clinical
many.
, simone.spuler@charite.de
. This is an open access article underKrahe, 2012). DM2 is an autosomal dominant multisystem disorder
caused by a CCTG repeat expansion of the cellular nucleic acid-binding
protein, CNBP (Liquori et al., 2001). Mutant transcripts lead to a toxic
RNA gain of function and miss-splicing of several effector genes
(Charlet-B et al., 2002; Tang et al., 2012). Many, but not all DM2
patients, complain of chronic muscle pain (George et al., 2004; Suokas
et al., 2012). The clinical features are highly variable and include
late-onset progressive muscle weakness, myotonia, cardiac conduction
defects, early-onset cataracts and insulin resistance (Rhodes et al.,
2012; Savkur et al., 2004; Udd and Krahe, 2012; Wahbi et al., 2009).
How the CNBPmutation confers risk for muscle pain in some patients
but not others is unknown and is the key question addressed in
this study.
Quantitative sensory testing (QST) is a standardized technique to
assess human somatosensory function and document altered nocicep-
tive signal processing (Backonja et al., 2013). By determining pain and
detection threshold to externalmechanical and thermal stimuli, sensorythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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iological mechanisms. QST profiles have been made of patients with
muscle-related disorders such as fibromyalgia, chronic back pain and
myogenic temporomandibular disease revealing similarities as well as
differences that may mirror distinct neurobiological mechanisms
(Blumenstiel et al., 2011; Pfau et al., 2009). We used a comprehensive
QST assessment to characterize the sensory phenotype of our cohort, a
pre-requisite for identifying molecular signatures of muscle pain. Our
analysis of the clinical and molecular profile of muscle pain in DM2
has enabled us to identify molecular signals in the affected muscle
that segregate with muscle pain.
2. Methods
2.1. Study design and participants
In this cross-sectional study we investigated a cohort of 42 DM2
patients and 20 age and gender-matched healthy controls between
March 2013 and January 2015. All DM2 patients were recruited from
Muscle Disorders Outpatient Clinic at Charité Campus Buch, Berlin,
Germany. The local ethics committee (EA1-127-14) approved the
study. All patients and healthy subjects signed the written informed
consent forms. Inclusion criteria were age N 18 years and molecularly
confirmed diagnosis of DM2. Exclusion criteria were additional neuro-
logical disorders that could affect sensory function (e.g. stroke) or treat-
mentwith opioid analgesics (Supplementary Fig. 1). Healthy volunteers
were excluded if they had diabetes, hypertension, neurological disor-
ders affecting sensory function, took analgesics or had muscle pain in
the last 3 months. We also obtained written informed consent from
12 DM2 patients, who underwent muscle biopsies for diagnostic pur-
poses between 2004 and 2014, to subject their stored muscle biopsy
specimens to RNA Seq analysis.
2.2. Clinical assessment of DM2 patients
Patients were asked about current unpleasant or painful sensations
in their muscles lasting for more than 3 months. They were asked to
rate the (1) unpleasant muscle sensation/pain, (2) muscle weakness
and (3) muscle stiffness on a visual analogue scale (score of 0 for “no
symptom” score of 10 for “worst imaginable intensity of symptom”).
Patients with DM2 were allocated to either the myalgia or no myalgia
group based on positive history of muscle pain and pain rating on the
testing day. Patients indicated on a drawingwhere the painwas located.
Frequency, duration, and modulating factors of pain such as tempera-
ture andmovementwere also recorded. Patients completed theGerman
version of the McGill Pain Questionnaire (MPQ). Pain rating index
(MPQ-PRI), number of words chosen (MPQ-NWC) and present pain
index (MPQ-PPI) were calculated. Past medical history was obtained
including presence of comorbidities, recent laboratory values, current
pain medication, smoking status, education and work status. Genetic
diagnosis of DM2 was performed at the Institute for Medical Genetics,
University of Würzburg, Germany.
2.3. Sensory testing protocols
We used a comprehensive, multimodal, QST protocol to generate
somatosensory profiles for each DM2 patient and healthy controls
(Rolke et al., 2006). We assessed pain thresholds for skin and muscle
tissue. Skin thermal and mechanical testing was performed in a
unilateral fashion (dominant hand side) over the hand dorsum,
shoulder and thigh. Thresholds for pressure pain were obtained
over eight muscles on the left and right side of the body: extensor
digitorum communis, deltoid, quadriceps and anterior tibialis. The
repertoire of pain tests included pressure pain threshold (PPT),
mechanical pain threshold (MPT), mechanical pain sensitivity
(MPS), dynamic mechanical allodynia and wind-up ratio (WUR).Thermal detection tasks included warm detection threshold (WDT),
cold detection threshold (CDT), heat pain threshold (HPT) (Frenzel
et al., 2012) and the paradoxical heat detection (PHS). Pain testing
procedures, instruments and methods were used strictly according
to those prescribed by the German research network on neuropathic
pain (Rolke et al., 2006).
2.4. Transcriptomic analysis of muscle tissue
Humanmuscle biopsy specimens were obtained fromM. quadriceps
femoris under sterile conditions and frozen in liquid nitrogen. Total
RNA from 12 DM2 biopsy specimens (6 patients with and 6 patients
without muscle pain) was isolated with RNeasy Mini Kit (Qiagen,
Germany) according to the manufacturer's instructions. RNA
quantity and purity were determined using a NanoDrop ND-1000
spectrophotometer (Thermo Scientific, USA) and an Agilent 2100
bioanalyser (Agilent Technologies, USA). The cDNA libraries were
prepared using TruSeq Stranded mRNA library preparation kit
(Illumina, USA). RNA paired-end sequencing was performed using
the Illumina HiSeq platform (Illumina, USA). Differentially expressed
genes were validated by qPCR using Sybr green assay at Stratagene
Mx3000P cycler (Agilent Technologies, USA) according tomanufacturer's
instructions. Sequences of the oligonucleotides are provided in
Supplementary Table 1.
2.5. Statistical analysis
All statistical calculations were performed using R software. The
QST parameters – CDT, WDT, PPT, WUR, MPS, MDT, and MPT – are
usually normally distributed in log-space and thus were log-
transformed. The QST-profiles of DM2 patients were compared to
controls using repeated measure two factorial (for group and tested
site) ANOVA. All QST measures from each patient were then
standardized by z-transformation with respect to the age- and
sex-matched healthy subject group.
Z score ¼ Meanindividual DM2−Meanhealthy subjects
 
=SDhealthy subjects
where mean individual DM2 is the value of the QST parameter in a DM2
patient, and meanhealthy subjects and SDhealthy subjects are mean and stan-
dard deviation of the corresponding QST parameter in the healthy con-
trol group. Z-scores signs were adjusted so that a z-score N 0 indicated
means gain of sensory function (lower threshold), and z-score b 0
means loss of function (increase in threshold). The advantage of
graphical representation of QST profiles as z-transformed data was to
directly compare between sensory modalities of different units and
ranges between groups and tested sites.
Gene expression data was analysed with CLC Genomic Workbench
v7.0 (Qiagen, Germany) and Qlucore Omics Explorer v3.1 (Qlucore,
Denmark). Samples obtained from patients without muscle pain were
considered as a reference group. Preprocessed raw sequences were
imported and trimmed in CLC Genomics Workbench and all trimmed
reads were aligned to the human reference genome (GRCh37) and
mapped back to the human transcriptome (v.19). Mapped read counts
were normalized using Trimmedmean ofM-values (TMM)method im-
plemented in Edge-R package. Normalized read counts were used for
analysis of differential gene expression at Qlucore Omics Explorer.
P values were calculated by two group comparison T-test. Genes
with P-value b0.05 and fold change N±1.8 were considered to be
differentially expressed and were presented as a heatmap with
hierarchical clustering of the samples. Differentially expressed
genes from RNAseq data were additionally confirmed with qPCR
using ΔΔCt method with the average of Ct values for GAPDH
and cyclophilin A used as a reference. Ct values were calculated by
MxPro qPCR software v4.1 (Agilent Technologies, USA). Gene
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(http://www.ebi.ac.uk/QuickGO/).3. Results
3.1. Patient characteristics
DM2 patient characteristics, EMG findings, information on
myotonia and MRC quantification of muscle weakness are listed in
Table 1 and Supplementary Table 2. None of the patients received
mexiletine. All 42 patients were ambulatory and attended the clini-
cal and QST assessment session. Data from 7 patients were excluded
from the analysis: six patients took opioid analgesics at the testing
day and one patient had sensory deficits due to stroke. Twenty
three patients reported muscle pain (DM2-myalgia group) and 12
did not (DM2-no-myalgia group). On a scale of 0–10, myalgias
were subjectively rated as most burdening in everyday activity
(5.7 ± 2.3) compared to muscle weakness (5.1 ± 2.8) and myotonia
(3.5 ± 2.8). Seventeen of 23 DM2 patients reporting myalgia had
experienced myalgia for more than 5 years. Muscle pain was typical-
ly localized symmetrically but the affected body region differed
between patients. The character of pain (assessed by the MPQ)
was: tugging (14/23), cramping (13/23), tiring (12/23), punishing
(10/23), annoying (9/23), radiating (8/23), burning (8/23) and dull
(6/23). Myalgias were reported as being worse during cold weather
in 10 patients. Of the 10 diabetic patients, one had a diagnosis of
diabetic polyneuropathy and trigeminal neuralgia but did not com-
plain of myalgia. Nine (39%) DM2 patients with myalgia had other
types of concurrent pain (low back pain, arthralgia, and headaches).
A higher proportion of patients with myalgia (18/23, 78%) had clini-
cal evidence of muscle weakness compared to DM2 patients without
myalgia (3/12, 25%) (P b 0.05, χ2-test). Otherwise there was no
difference in the frequency of comorbidities (diabetes mellitus,
cataracts, and dyslipidemias) between the groups. Twenty healthy
subjects (11 females and 9 males) were recruited with a mean ±
SD age of 55 ± 8.3 years (P N 0.05 t-test, compared to DM2). TheTable 1
Summary of characteristics of DM2 patients.
Myalgia No myalgia Total
N 23 12 35
Age, y 57.3 ± 10.3 48.6 ± 15.2 54.3 ± 12.7
Male/female 9/14 7/5 16/19
BMI, kg/m2 26.2 ± 4.5 24.4 ± 4.8 25.6 ± 4.6
Muscle features
Muscle weakness 15 (68%) 5 (42%) 20 (63%)
Myotonia 19 (85%) 7 (58%) 26 (63%)
Systemic features
Insulin resistance 4 (17%) 1 (8%) 5 (14%)
Hyperlipidemia 11 (48%) 5 (42%) 16 (46%)
Cataract 8 (35%) 3 (25%) 11 (46%)
Hypertension 11 (48%) 5 (42%) 16 (46%)
Cardiac conduction abnormalities 7 (30%) 1 (6%) 8 (23%)
CK 286 ± 196 506 ± 414
Pain features
Pain intensity, NAS 4.2 ± 2.2 NA
Pain duration, y 7.4 ± 3.3 NA
Pain location
Thigh 16
Shoulder 14
Back 8
Lower arm 9
Lower leg 8
Myalgia related to movement 10 (43%) NA
Myalgia related to cold 14 (61%) NA
MPQ
PRI 8.3 NA
MWC 16.1 NA
PPI 3.3 NAproportion of males and females between DM2 (54% females) and
healthy controls (55% females) was comparable.
3.2. Sensory changes in patients with DM2
Amongst all the QST measures (Fig. 1, Supplementary Tables 3 and
4) themost prominent abnormalitywas seen in pressure pain threshold
(PPT). Repeated-measures ANOVA indicated a statistically significant
decrease in pressure pain threshold in the DM2-myalgia group
compared with the control groups. There is a general and strong shift
for mean pressure pain thresholds towards hyperalgesia in patients
with DM2, with mean z-score values for DM2 patients with myalgia
lying beyond the healthy subject range of 2 z-score units (Fig. 1A and
Supplementary Table 3). Between-group comparisons (Fig. 1) reveal
significant differences, in the gain-of-function direction, between the
healthy subject groups and the DM2-no-myalgia and DM2-myalgia
groups for all muscle groups (P b 0.0001, ANOVA). The number
(percentage) of DM2-myalgia patients with z-scores for PPT
lying beyond +1.96 (170 KPa for EDC, 200 KPa for deltoid, 265 KPa
for anterior tibialis, and 265 KPa for the quadriceps) are 9(39%),
15(65%), 13(57%), and 16(70%) for EDC, deltoid, anterior tibialis,
and quadriceps muscles respectively. This contrasts with 1(8%),
1(8%), 2(16%), and 2(16%) for EDC, deltoid, anterior tibialis, and
quadriceps muscles respectively in DM2-no-myalgia patients.
Themedian z-scores for all thermal andmechanical pain parameters
in theDM2 group generally fallwithin the healthy subject ranges except
for a few individuals (Fig. 1B & C). Within mechanical pain parameters,
all DM2 participants showed a slight loss of MPT function, i.e., increased
pain threshold to pinprick stimulation, compared to healthy subjects
(P=0.03, ANOVA).When comparingDM2patients,we foundno signif-
icant differences in MPT, however, we observed enhanced subjective
rating to pinprick stimuli (MPS) and increased windup ratio in
DM2-myalgia compared to DM2-no-myalgia group (Supplementary
Fig. 2, Supplementary Table 4). Thus DM2 patients with myalgia exhib-
ited increased MPS and windup ratios (+ve z-score, gain of function)
typical for patients with generalized central sensitization (P = 0.03,
ANOVA). Allodynia occurred in onepatientwithmyalgia in the shoulder
region. A total of 3 subjects with DM2 (two with myalgia, one without
myalgia and one healthy subject) reported paradoxical heat sensations.
Interestingly, mechanical detection threshold was significantly in-
creased in DM2 patients indicating that touch sensation was impaired
in all DM2 patients [median/inter quartile range in mN in healthy
subject 1.1/0.7 (hand), 2.0/2.0 (shoulder), and 4.5/4.1 (thigh); in DM2
patients 3.2/3.1 (hand), 4.0/8.9 (shoulder), and 8.0/7.8 (thigh)]. The
mean z-score values for MDT reveal a loss of function in the DM2
group compared to healthy subjects (Supplementary Table 2). This
effect held true after excluding the 10 diabetic patients (data not
shown). We observed loss of thermal warming discrimination and
therefore a loss of sensory function in four DM2 patients (two with
and two without myalgia). Paradoxical heat sensation was observed in
two DM2-myalgia patients, one DM2-no-myalgia patient and one
healthy control subject.
3.3. Myalgic and non-myalgic DM2 muscle has distinct transcriptome
profiles
We analysed transcriptome profiles of muscle biopsy specimens
obtained from myalgic and non-myalgic, age-matched DM2 patients
(n = 6 for each group, Supplementary Table 5). Grouping of muscle
biopsies into myalgic and nonmyalgic groups was based on document-
ed chronic myalgia in the medical records. Myopathological findings
were typical for DM2 (Meola and Cardani, 2015) and similar in both
groups (Supplementary Table 5). Bioinformatic analysis of muscle
RNAseq data revealed 14, muscle-specific, differentially expressed
(DE) genes based on presence or absence of myalgia (Fig. 2 and
Supplementary Table 6). Due to limited muscle tissue material, only
Fig. 1. Plots of QST parameters for pressure, thermal andmechanical pain. (A) Scatter and box andwhisker plots of pressure pain threshold across the 4muscle groups in healthy subjects,
DM2-myalgia and DM2-no-myalgia groups. (B) Thermal and (C) mechanical pain QST parameters represented as scatter and box and whisker plots of z-scores over the 3 tested
areas (hand, shoulder, and thigh). Mean of the healthy subject z-core is represented by “0” and dotted lines designating ±1.96 SD. EDC, M. extensor digitorum communis; CPT,
cold pain threshold; HPT, heat pain threshold; PPT, pressure pain threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; WUR, wind-up ratio; MPT, mechanical
pain threshold.
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the RNASeq analysis (Supplementary Table 6). The highest differential
expression found was a decrease in the levels of monoamine oxidase
A (MAOA) in myalgic DM2 patients. MAOA encodes an enzyme that
degrades amine neurotransmitters, such as dopamine, norepinephrine,
and serotonin. Another genewith decreased expression inmyalgic DM2
was activity-regulated cytoskeleton-associated protein (ARC).
Significantly increased expression in myalgic DM2 muscle were
found for CYB5D1, GSTCD, GRB14, PANK1, ZNF711, FAM26E, PFKFB2,
ZNF841, HECW2, SLC16A12, FRMPD1, NR4A3 and SLC16A12. Analysis
of gene functions showed that these genes are involved in transcrip-
tional regulation (NR4A3, ZNF711 and ZNF841), metabolic regulation
(PANK1, PFKFB2), ubiquitin ligation (HECW2), signal transduction
(GRB14), iron binding (CYB5D1), creatine transmembrane transport
(SLC16A12) or predicted cation channel activity (FAM26E).
4. Discussion
Weprovide compelling evidence thatmyalgia in DM2patients could
be initiated and maintained by molecular changes within the muscle.
This interpretation is supported by our discovery that distinct
transcriptome profiles segregate myalgic from non-myalgic patients.
In principle miss-splicing of CNBP targets in the nervous system or
other tissues could contribute to myalgia. However, if centralnervous system mechanisms were primary a molecular signature
for the presence of pain would not be expected in the muscle.
Decreased pressure pain thresholds (PPT) in myalgic DM2 patients
indicate that the myalgia could be initiated by peripheral mecha-
nisms within the muscle (Graven-Nielsen and Arendt-Nielsen,
2010). Our data is supported by an earlier study that found lowered
PPT in DM2 patients distinct from pain associated with other muscle
disease (George et al., 2004). Peripheral sensitization mechanisms
are prominent in muscle and are known to be a trigger for central
sensitization (Graven-Nielsen and Mense, 2001; Lewin et al., 2014;
Mense, 2003). Central sensitization was likely present in myalgic
DM2 patients as evidenced by a slightly elevated wind-up compared
to non-myalgic DM2 patients but not in healthy subjects. We further
observed that sensation to non-painful stimuli in DM2 patients was
suppressed, independent of the presence of muscle pain. There are
various conditions associated with chronic muscle pain, fibromyal-
gia, low back and neck pain, and these disease entities show different
sensory profiles as measured with psychometric methods. However,
presentation of myalgia in DM2 patients may be easily misdiagnosed
as fibromyalgia (Auvinen et al., 2008). In fibromyalgia there is a
generalized mechanical and thermal hypersensitivity and touch
modalities are usually unaffected (Blumenstiel et al., 2011).
Wind-up ratio elevation has been observed in fibromyalgia syndrome
(Staud et al., 2001). Thus there are differences but also similarities
Fig. 2. Transcriptome profile differences betweenmuscle tissues derived fromDM2patientswithmyalgia andwithoutmyalgia. (A) Heatmap showing expression patterns of differentially
expressed genes (DEG) based on the presence or absence of myalgias. Each row in the heat map indicates gene expression values for one of 14 differentially expressed genes while every
column shows gene expression profile for one of the 12 tested DM2 patients. Areas in green correlate with low and areas in red correlate with high gene expression (see scale).
(B) Normalized reads per gene for the DEGs.
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fibromyalgia. In contrast, QST profiles in chronic low back pain
patients reveal localized alterations such as lowered PPT (Blumenstiel
et al., 2011; Gerhardt et al., 2015).We noted however that few patients
with DM2 with myalgia have generalized lowered mechanical and
thermal (cold and heat) thresholds. Whether such spatial and modality
spread in sensory profiles represents a separate pain processing
mechanisms or related to disease progression remains to be clarified.
TheDM2patients studied here showed nodifferences in age, current
medication or histopathology of muscle tissue depending on whether
they were myalgic or non-myalgic. Thus we have no evidence that the
differences observed in the transcriptome of myalgic and non-myalgic
DM2 muscle was based on anything else besides the presence of pain.
It is known that certain types of ion channels are miss-spliced in myo-
tonic dystrophies (Charlet-B et al., 2002; Tang et al., 2012). Abnormal
splicing and downregulation of ubiquitin ligase,NEDD4, in DM2patients
prescribed HMG Co-A reductase inhibitors (statins) has been associated
with adverse reactions (Screen et al., 2014). Also, hyperlipidemia and
insulin resistance are common in DM2 patients, suggesting that elevat-
ed endogenous lipid levels could conceivably contribute to muscle pain
in DM2 (Piomelli and Sasso, 2014; Heatwole et al., 2011).
DM2 transcriptomic profiles identified 14 differentially expressed
genes, which possibly contribute to the onset of myalgias in DM2
patients. One of the identified differentially expressed genes encodes
monoamine oxidase A (MAOA). Polymorphisms in the MAOA gene
have been proposed to segregate with low and high pain responders,
however, the genetic evidence is weak (Di Lorenzo et al., 2014;
Kim et al., 2006). MAOA has been proposed as a therapeutictarget in fibromyalgia and treatment with a specific MAOA inhibitor,
moclobemide, was administered to female patients with fibromyalgia
in an earlier study (Hannonen et al., 1998). Moclobemide significantly
decreased pain in fibromyalgia patients at the end of a 12 weeks inter-
vention period by 1.2 points on the VAS (5.7 to 4.5) compared to place-
bo group. Variations in MAOA have been associated with different
perceptions of pain and pain-related evoked potentials (Di Lorenzo
et al., 2014; Treister et al., 2011). Two recent studies also quantified
MAOA gene expression in human muscle biopsies and have associated
high expression with insulin resistance (Elgzyri et al., 2012; Mason
et al., 2011). In the context of insulin resistance, common in DM2, one
of the up-regulated genes in myalgic patients was growth factor
receptor-bound protein 14 (GRB14) which is a known negative
regulator of insulin receptor signalling (Depetris et al., 2005). Another
interesting finding was elevated expression of creatine transporter
SLC16A12 in myalgic DM2 which might be related to increased muscle
wasting and inflammatory pain (Abplanalp et al., 2013). Interesting-
ly, there is already a small molecule inhibitor identified for the
6-phosphofructo-2-kinase (PFKFB2) enzyme (Telang et al., 2012)
the expression of which was up-regulated in the muscle of DM2
patient with myalgia. Thus, our approach may open new avenues
to explore the link between novel genes associated with pain and
therapeutic interventions at least in animal models.
Our study has several limitations. The time points of molecular
and sensory phenotyping were different. The reasons are mainly the
invasiveness of the muscle biopsy procedure which requires strict
indications. In the light of disease progression with time, and the small
sample size, there might have been some unaccounted confounders
210 R. Moshourab et al. / EBioMedicine 7 (2016) 205–211affecting gene expression other than myalgia despite similar muscle
histopathology. Future research should consider concomitant phenotyp-
ing tomakedirect correlations betweenmolecular changes in themuscle
and changes in sensory phenotype in patients with myalgia. As to QST
profiling, the group size was small with 12–23 subjects. QST profiles
vary with age and sex and our DM2 cohort was matched with a healthy
control group. Furthermore, the QST protocol relies on subjective rating
of the participant andmight reflect behaviour instead of pain thresholds.
Finally,we applied the same testing protocol to all patients although they
presented with different spatial patterns of pain; however, our results
are controlled for by test site using ANOVA analysis.
High variability in pain character and pathophysiology in patients
with chronic pain has made it difficult to identify tailored pain medica-
tion that show selective efficacy in sub-populations of patients. Howev-
er, emerging genomic strategies might facilitate the development of
new and more effective pain therapeutics (Dib-Hajj and Waxman,
2014). The molecular signature of myalgia shown in this study may
also help to identify pathways that are associated with pain in other
conditions affecting skeletal muscle. Identifying the molecular source
of pain pathophysiology should greatly facilitate focussing effective
treatments, although major hurdles remain.
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